Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia

In the present paper we have studied the quantitative variations in estrogen (ER) and progesterone receptor (PR) content of breast cancer induced by tamoxifen. In addition to receptors, hormonal levels of estradiol, progesterone, prolactin, FSH, LH and testosterone were also measured. The cases included in our study were consecutively selected among those breast cancers in which an aliquot of the tissue sample sent for analysis of the steroid receptors was positive for cancer and also found to have at least one of the steroid receptors positive, not only in the biopsy but also in the surgical specimen. Following this criterion, we finally collected 14 cases of breast cancer treated daily with 30 mg of tamoxifen during an interval of 3 weeks from the initial biopsy to the final surgery. From our results we can conclude that tamoxifen reduced significantly the ER concentration while no changes were observed in PR values. Concerning hormones, while in premenopausal patients tamoxifen induced a rise in plasma estradiol, in postmenopausal women the only modification observed was a decrease in plasma FSH. The variation in steroid receptor content under tamoxifen therapy may also contribute to the evaluation of the hormone dependency of gynecologic malignancies.

show abstract

“…These findings might reflect the inherent difficulties in the sampling of a potentially heterogeneous tumor [15].…”

Section: Discussionmentioning

confidence: 85%

Variation of Estrogen and Progesterone Receptor Status in Breast Cancer after Tamoxifen Therapy

et al. 1990

View full text Add to dashboard Cite

show abstract

“…These include medroxyprogesterone acetate (MPA), with response rates of 14-53% (Thigpen et al, 1999), and tamoxifen citrate (TMC), with response rates of 10-20% (Thigpen, Brady, & Homesley, 2001) (Figure 1). Estrogenic compounds such as TMC have been shown to increase progesterone receptors in human endometrial cancers (Carlson, Allegra, Day, & Wittliff, 1984;Mortel et al, 1981) and, therefore, could theoretically increase the effectiveness of progestational agents in the treatment of endometrial carcinoma. Therefore, coadministration of TMC and MPA is preferred to increase the response rate and the percentage recovery in patients with endometrial carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous TLC–densitometric determination of tamoxifen citrate and medroxyprogesterone acetate and UV‐degradation kinetic study of medroxyprogesterone acetate

Saleh

Abdel‐aal

Abbas

2018

Biomedical Chromatography

View full text Add to dashboard Cite

Coadministration of tamoxifen citrate (TMC) and medroxyprogesterone acetate (MPA) is preferred to increase the response rate and the percentage recovery in patients with endometrial carcinoma. Administration of TMC and MPA and their combination affects estrogen and progestin receptor concentrations in advanced endometrium carcinoma by affecting 17β-hydroxyl steroid dehydrogenase activity and serum hormone concentrations. A sensitive, accurate and robust thin-layer chromatography method has been established for simultaneous analysis of TMC and MPA. Method development was carried out on silica gel F using butanol-acetic acid-water (6:0.5:0.5, v/v/v) as mobile phase. Densitometric scanning was carried out at 241 nm for simultaneous detection of TMC and MPA. Retardation factor (R ) values for TMC and MPA were 0.21 and 0.85, respectively. The method was validated according to ICH guidelines. Regression plots revealed linear relationships in the concentration range of 50-500 and 25-250 ng/band for TMC and MPA, successively. Accuracy was ≥99.60 and 98.72% for TMC and MPA, respectively. Forced degradation studies using UV photodegradation was applied on MPA after exposure to UV light for different times and applying a kinetic study for calculating the degradation rate constant (k) and half-life time (t ).

show abstract

“…Figure 2 shows the schematic illustration of the distribution of cancer tissues in the asymmetrical double uterus. Despite postoperative hormone ther apy (tamoxifen plus progestin) [7], the patient died of lung metasta sis after 14 months. …”

Section: Case Reportmentioning

confidence: 99%

Endometrial Carcinoma Arising from a Double Uterus

Tsukahara

Tomita

et al. 1990

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

Tamoxifen and endometrial carcinoma: Alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia

Cited by 5 publications

References 0 publications

Variation of Estrogen and Progesterone Receptor Status in Breast Cancer after Tamoxifen Therapy

Variation of Estrogen and Progesterone Receptor Status in Breast Cancer after Tamoxifen Therapy

Simultaneous TLC–densitometric determination of tamoxifen citrate and medroxyprogesterone acetate and UV‐degradation kinetic study of medroxyprogesterone acetate

Endometrial Carcinoma Arising from a Double Uterus

Contact Info

Product

Resources

About